Markets:

Overview

News

Currencies

International

Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

29.29 +0.29 (+1.00%)

Streaming Delayed Price Updated: 1:40 PM EDT, Jul 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

December 09, 2024

From Genmab A/S

Via Business Wire

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

December 08, 2024

From Genmab A/S

Via Business Wire

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

December 07, 2024

From Genmab A/S

Via Business Wire

NASDAQ:GMAB stands out as a growth opportunity that won't break the bank. ↗

November 18, 2024

NASDAQ:GMAB, a growth stock which is not overvalued.

Via Chartmill

A Closer Look at 10 Analyst Recommendations For Genmab ↗

November 08, 2024

Via Benzinga

Why NASDAQ:GMAB Is a Standout High-Growth Stock in a Consolidation Phase. ↗

November 29, 2024

Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation.

Via Chartmill

For those who appreciate value investing, NASDAQ:GMAB is a compelling option with its solid fundamentals. ↗

November 25, 2024

Despite its impressive fundamentals, GENMAB A/S -SP ADR (NASDAQ:GMAB) remains undervalued.

Via Chartmill

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

November 05, 2024

From Genmab A/S

Via Business Wire

Preview: Genmab's Earnings ↗

November 05, 2024

Via Benzinga

NASDAQ:GMAB: a strong growth stock preparing for the next leg up?. ↗

October 30, 2024

Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation.

Via Chartmill

When you look at NASDAQ:GMAB, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗

October 29, 2024

GENMAB A/S -SP ADR (NASDAQ:GMAB) appears to be flying under the radar despite its strong fundamentals.

Via Chartmill

12 Analysts Have This To Say About Genmab ↗

October 16, 2024

Via Benzinga

NASDAQ:GMAB qualifies as a high growth stock and is consolidating. ↗

October 09, 2024

GENMAB A/S -SP ADR (NASDAQ:GMAB)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.

Via Chartmill

NASDAQ:GMAB is an undervalued gem with solid fundamentals. ↗

October 08, 2024

Don't overlook GENMAB A/S -SP ADR (NASDAQ:GMAB)—it's a hidden gem with strong fundamentals and an attractive price tag.

Via Chartmill

Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced. ↗

October 28, 2024

GENMAB A/S -SP ADR (NASDAQ:GMAB) is showing good growth, while it is not too expensive.

Via Chartmill

NASDAQ:GMAB, a growth stock which is not overvalued. ↗

October 07, 2024

NASDAQ:GMAB is showing good growth, while it is not too expensive.

Via Chartmill

Jin Medical International, Nio And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

September 23, 2024

Via Benzinga

NASDAQ:GMAB is probably undervalued for the fundamentals it is displaying. ↗

September 17, 2024

GENMAB A/S -SP ADR (NASDAQ:GMAB) is an undervalued gem with solid fundamentals.

Via Chartmill

Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation. ↗

September 16, 2024

Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

September 15, 2024

From Genmab A/S

Via Business Wire

Expert Ratings For Genmab ↗

September 09, 2024

Via Benzinga

NASDAQ:GMAB: a strong growth stock preparing for the next leg up?. ↗

September 03, 2024

Is GENMAB A/S -SP ADR (NASDAQ:GMAB) on the Verge of a Major Breakout as a Strong Growth Stock?

Via Chartmill

NASDAQ:GMAB is showing good growth, while it is not too expensive. ↗

August 26, 2024

GENMAB A/S -SP ADR (NASDAQ:GMAB) is not too expensive for the growth it is showing.

Via Chartmill

Decoding 10 Analyst Evaluations For Genmab ↗

August 20, 2024

Via Benzinga

TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

August 19, 2024

From Genmab A/S

Via Business Wire

Genmab Announces Changes to its Executive Committee

August 16, 2024

From Genmab A/S

Via Business Wire

On Holding Reports Mixed Q2 Results, Joins Tencent Music Entertainment And Other Big Stocks Moving Lower In Tuesday Pre-Market Session ↗

August 13, 2024

Via Benzinga

GMAB Stock Earnings: Genmab Misses EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

GMAB stock results show that Genmab missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Via InvestorPlace

BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products ↗

August 05, 2024

BioNTech posted a significant Q2 2024 loss of 807.8 million euros. Sales dropped to 128.7 million euros as the demand for COVID-19 vaccines shifted. R&D expenses rose due to late-stage oncology...

Via Benzinga

While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable. ↗

August 05, 2024

While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.